Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical study of BIO101 (20-hydroxyecdysone) in obesity.
The study will measure muscle strength, mobility and body composition. It is due to start mid-2024 in the United States and could be extended to Europe.
Biophytis expects preliminary results in 2025 and is seeking funding and partnerships to complete the study.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option